Liver Diseases News - LARVOL Sigma

Liver Diseases	Welcome, Profile Billing Logout

«1 2...84 85 86 87 888990 91 92 93 94...98 99 »

||||||||||  tilsotolimod (IMO-2125) / Idera
Trial completion:  Study of Combination Treatment With IMO-2125 and Ribavirin in Na (clinicaltrials.gov) -  May 14, 2012
P1, N=50, Completed,  Sponsor: Idera Pharmaceuticals, Inc.
Recruiting --> Completed

||||||||||  tilsotolimod (IMO-2125) / Idera
Trial completion, Immunomodulating:  Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients (clinicaltrials.gov) -  May 14, 2012
P1, N=40, Completed,  Sponsor: Idera Pharmaceuticals, Inc.
Recruiting --> Completed Recruiting --> Completed

||||||||||  exatecan mesylate (DX-8951f) / Daiichi Sankyo
Trial completion:  DX-8951f in Treating Patients With Biliary Cancer (clinicaltrials.gov) -  May 14, 2012
P2, N=0, Completed,  Sponsor: Daiichi Sankyo Inc.
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Clinical: Probiotics for Liver Cirrhosis With Portal Hypertension (clinicaltrials.gov) - May 13, 2012
P=N/A, N=120, Recruiting, Sponsor: Po-Lin Chen, MD

||||||||||  INX 189 / BMS, Daklinza (daclatasvir) / BMS
Enrollment change:  Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin (clinicaltrials.gov) -  May 13, 2012
P2, N=210, Completed,  Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=90 --> 210

||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Metastases:  E7080-J081-202: Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) -  May 13, 2012
P1/2, N=66, Active, not recruiting,  Sponsor: Eisai Co., Ltd.
N=90 --> 210 N=11 --> 66

||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases:  E7080-J081-202: Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) -  May 13, 2012
P1/2, N=66, Active, not recruiting,  Sponsor: Eisai Co., Ltd.
N=11 --> 66 Recruiting --> Active, not recruiting

||||||||||  Pegasys (pegylated interferon α -2a) / Roche
New P4 trial, Combination therapy:  Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C (clinicaltrials.gov) -  May 9, 2012
P4, N=272, Completed,  Sponsor: Asan Medical Center

|||||||||| New P3 trial: Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection (clinicaltrials.gov) - May 8, 2012
P3, N=270, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center

||||||||||  Tyzeka (telbivudine) / Novartis
New P3 trial:  TERESA: Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B (clinicaltrials.gov) -  May 8, 2012
P3, N=184, Recruiting,  Sponsor: Asan Medical Center

||||||||||  Tyzeka (telbivudine) / Novartis
Enrollment open:  TERESA: Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B (clinicaltrials.gov) -  May 8, 2012
P3, N=184, Recruiting,  Sponsor: Asan Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Enrollment change:  Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA (clinicaltrials.gov) -  May 6, 2012
P4, N=72, Completed,  Sponsor: Yonsei University
Not yet recruiting --> Recruiting N=200 --> 72

||||||||||  Tyzeka (telbivudine) / Novartis
Clinical:  EBEREST: Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine (clinicaltrials.gov) -  May 6, 2012
P3, N=30, Completed,  Sponsor: Novartis Pharmaceuticals
N=200 --> 72 Recruiting --> Completed

||||||||||  entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion:  Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA (clinicaltrials.gov) -  May 6, 2012
P4, N=72, Completed,  Sponsor: Yonsei University
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion:  Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA (clinicaltrials.gov) -  May 6, 2012
P4, N=72, Completed,  Sponsor: Yonsei University
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Tyzeka (telbivudine) / Novartis
Trial completion:  An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B (clinicaltrials.gov) -  May 6, 2012
P4, N=44, Completed,  Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  nintedanib / Generic mfg.
New P1 trial:  Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma (clinicaltrials.gov) -  May 6, 2012
P1, N=29, Recruiting,  Sponsor: Boehringer Ingelheim

|||||||||| New P1 trial: A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1) (clinicaltrials.gov) - May 6, 2012
P1, N=30, Completed, Sponsor: Merck Sharp & Dohme Corp.

||||||||||  pradigastat (LCQ908) / Novartis
Trial termination, Monotherapy:  A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients (clinicaltrials.gov) -  May 5, 2012
P2, N=32, Terminated,  Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Terminated; Terminated early due to futility

||||||||||  pradigastat (LCQ908) / Novartis
Enrollment change, Monotherapy:  A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients (clinicaltrials.gov) -  May 5, 2012
P2, N=32, Terminated,  Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; Terminated early due to futility N=57 --> 32

||||||||||  SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion:  SIRTACE: SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  May 3, 2012
P2, N=28, Completed,  Sponsor: Sirtex Medical
N=57 --> 32 Recruiting --> Completed

||||||||||  alisporivir (DEB-025) / Debiopharm, Solid BioSci
Trial termination, Combination therapy:  Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C (clinicaltrials.gov) -  May 3, 2012
P3, N=6, Terminated,  Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Withdrawn --> Terminated

||||||||||  Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Clinical:  Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients (clinicaltrials.gov) -  May 2, 2012
P=N/A, N=20, Recruiting,  Sponsor: University of Chicago

||||||||||  Tyzeka (telbivudine) / Novartis
Trial completion:  Chinese PAC: Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B (clinicaltrials.gov) -  May 2, 2012
P4, N=2200, Completed,  Sponsor: Novartis Pharmaceuticals
Withdrawn --> Terminated Recruiting --> Completed

||||||||||  alisporivir (DEB-025) / Debiopharm, Solid BioSci
Enrollment change, Combination therapy:  Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C (clinicaltrials.gov) -  May 2, 2012
P3, N=6, Terminated,  Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=150 --> 6

||||||||||  Pegasys (pegylated interferon ? -2a) / Roche, Victrelis (boceprevir) / Roche, Merck (MSD)
New P4 trial, Combination therapy:  A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C (clinicaltrials.gov) -  May 2, 2012
P4, N=165, Active, not recruiting,  Sponsor: Hoffmann-La Roche

||||||||||  vesatolimod (GS-9620) / Gilead
New P1 trial:  A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C (clinicaltrials.gov) -  May 2, 2012
P1, N=51, Completed,  Sponsor: Gilead Sciences

||||||||||  Tyzeka (telbivudine) / Novartis
Trial completion:  To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB) (clinicaltrials.gov) -  May 2, 2012
P4, N=100, Completed,  Sponsor: Novartis Pharmaceuticals
N=150 --> 6 Recruiting --> Completed

||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment change:  Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant (clinicaltrials.gov) -  May 1, 2012
P2, N=40, Completed,  Sponsor: Gilead Sciences
Recruiting --> Completed N=50 --> 40

||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion:  Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant (clinicaltrials.gov) -  May 1, 2012
P2, N=40, Completed,  Sponsor: Gilead Sciences
N=50 --> 40 Active, not recruiting --> Completed

||||||||||  vesatolimod (GS-9620) / Gilead
New P1 trial:  A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) -  May 1, 2012
P1, N=51, Completed,  Sponsor: Gilead Sciences

||||||||||  vesatolimod (GS-9620) / Gilead
New P1 trial:  A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B (clinicaltrials.gov) -  May 1, 2012
P1, N=49, Completed,  Sponsor: Gilead Sciences

||||||||||  ALS-2200 / J&J, Vertex, BMS
New P1 trial:  First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) -  May 1, 2012
P1, N=80, Active, not recruiting,  Sponsor: Alios Biopharma Inc.

||||||||||  Tyzeka (telbivudine) / Novartis
Trial withdrawal:  Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B (clinicaltrials.gov) -  Apr 30, 2012
P4, N=0, Withdrawn,  Sponsor: Novartis
Active, not recruiting --> Completed Terminated --> Withdrawn

||||||||||  Tyzeka (telbivudine) / Novartis
Enrollment change:  Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B (clinicaltrials.gov) -  Apr 30, 2012
P4, N=0, Withdrawn,  Sponsor: Novartis
Terminated --> Withdrawn N=184 --> 0

||||||||||  acetylcysteine solution / Generic mfg., paracetamol / Generic mfg.
Trial completion:  A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. (clinicaltrials.gov) -  Apr 30, 2012
P3, N=184, Completed,  Sponsor: University of Pittsburgh
N=184 --> 0 Active, not recruiting --> Completed

||||||||||  JNJ-47910382 / J&J
Trial completion:  A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 (clinicaltrials.gov) -  Apr 30, 2012
P1, N=35, Completed,  Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  MK-6325 / Merck (MSD)
Trial completion:  Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003) (clinicaltrials.gov) -  Apr 30, 2012
P1, N=36, Completed,  Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  entecavir / Generic mfg.
Enrollment change:  Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection (clinicaltrials.gov) -  Apr 29, 2012
P3, N=109, Completed,  Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=50 --> 109

|||||||||| Trial completion: Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age (clinicaltrials.gov) - Apr 29, 2012
P3, N=175, Completed, Sponsor: Novartis Vaccines
N=50 --> 109 Recruiting --> Completed

|||||||||| Trial completion: HALT-HE: A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (clinicaltrials.gov) - Apr 29, 2012
P2, N=193, Completed, Sponsor: Hyperion Therapeutics, Inc.
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  midodrine hydrochloride / Generic mfg.
New P2 trial:  Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure (clinicaltrials.gov) -  Apr 26, 2012
P2, N=15, Not yet recruiting,  Sponsor: Fundacion Clinic per a la Recerca Biomédica

||||||||||  Avastin (bevacizumab) / Roche
Trial completion, Metastases:  Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001 (clinicaltrials.gov) -  Apr 26, 2012
P2, N=33, Completed,  Sponsor: Gerhard Treiber
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  pioglitazone / Generic mfg.
Enrollment closed:  University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) (clinicaltrials.gov) -  Apr 25, 2012
P4, N=90, Active, not recruiting,  Sponsor: The University of Texas Health Science Center at San Antonio
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Byetta (exenatide) / AstraZeneca
Trial completion:  Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) -  Apr 25, 2012
P4, N=24, Completed,  Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Victrelis (boceprevir) / Roche, Merck (MSD)
New P3 trial:  LeeG3: Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment (clinicaltrials.gov) -  Apr 24, 2012
P3, N=21, Active, not recruiting,  Sponsor: University of Calgary

||||||||||  JNJ-47910382 / J&J
New P1 trial:  A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients (clinicaltrials.gov) -  Apr 24, 2012
P1, N=18, Recruiting,  Sponsor: Janssen R&D Ireland

|||||||||| Trial completion: Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis (clinicaltrials.gov) - Apr 24, 2012
P3, N=158, Completed, Sponsor: Catalysis SL
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Pegasys (pegylated interferon ? -2a) / Roche
New P4 trial, Combination therapy:  A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) (clinicaltrials.gov) -  Apr 23, 2012
P4, N=30, Completed,  Sponsor: Hoffmann-La Roche

||||||||||  candesartan cilexetil / Generic mfg.
Trial withdrawal:  Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C (clinicaltrials.gov) -  Apr 22, 2012
P2, N=0, Withdrawn,  Sponsor: Kaiser Permanente
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn



	Diseases Companies Products Productz Mechanisms of Action Sites